UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2023
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
GSK plc (the ‘Company’)
Transaction notification
1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
a) | Name | Mr Urs Rohner | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Purchase of 490 Ordinary Shares | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£14.066 | 490 | ||||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-03-20 | |||
f) | Place of the transaction | London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
a) | Name | Charles Bancroft | |||
b) | Position/status | Senior Independent Non-Executive Director | |||
c) | Initial notification/amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares (‘ADSs’) ISIN: US37733W2044 | |||
b) | Nature of the transaction | Purchase of 1,861 ADSs | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$34.5033 | 1,861 | ||||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-03-20 | |||
f) | Place of the transaction | New York Stock Exchange (XNYS) |
Details of PDMR/person closely associated with them (‘PCA’) | |||||
a) | Name | Dr Hal Barron | |||
b) | Position/status | Non-Executive Director | |||
c) | Initial notification/amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares (‘ADSs’) ISIN: US37733W2044 | |||
b) | Nature of the transaction | Purchase of 242 ADSs | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$34.5033 | 242 | ||||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-03-20 | |||
f) | Place of the transaction | New York Stock Exchange (XNYS) |
1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
a) | Name | Dr Anne Beal | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares (‘ADSs’) ISIN: US37733W2044 | |||
b) | Nature of the transaction | Purchase of 241 ADSs | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$34.5033 | 241 | ||||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-03-20 | |||
f) | Place of the transaction | New York Stock Exchange (XNYS) |
1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
a) | Name | Dr Hal Dietz | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares (‘ADSs’) ISIN: US37733W2044 | |||
b) | Nature of the transaction | Purchase of 241 ADSs | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$34.5033 | 241 | ||||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-03-20 | |||
f) | Place of the transaction | New York Stock Exchange (XNYS) |
1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
a) | Name | Dr Jesse Goodman | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares (‘ADSs’) ISIN: US37733W2044 | |||
b) | Nature of the transaction | Purchase of 241 ADSs | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$34.5033 | 241 | ||||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-03-20 | |||
f) | Place of the transaction | New York Stock Exchange (XNYS) |
1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
a) | Name | Elizabeth (Liz) McKee Anderson | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares (‘ADSs’) ISIN: US37733W2044 | |||
b) | Nature of the transaction | Purchase of 473 ADSs | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$34.5033 | 473 | ||||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-03-20 | |||
f) | Place of the transaction | New York Stock Exchange (XNYS) |
1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
a) | Name | Dr Vishal Sikka | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares (‘ADSs’) ISIN: US37733W2044 | |||
b) | Nature of the transaction | Purchase of 838 ADSs | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$34.5033 | 838 | ||||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-03-20 | |||
f) | Place of the transaction | New York Stock Exchange (XNYS) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GSK plc | |
(Registrant) | |
Date: March 21, 2023 | |
By:/s/ VICTORIA WHYTE -------------------------- | |
Victoria Whyte | |
Authorised Signatory for and on | |
behalf of GSK plc |